HCPLive Network

Multiple Sclerosis

Paul Wicks, PhD, discusses the surge in Internet-savvy patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Don Mahad, MD, PhD, discusses his research’s focus of protecting nerve cells at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Alasdair Coles, MD, University of Cambridge, shares his thoughts on the efficacy of alemtuzumab for patients with multiple sclerosis (MS) at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Assessment of long-term data on treatment utility demonstrates the effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate for multiple sclerosis.
Treatment with Sativex oromucosal spray produces significant reductions in spasticity in patients with multiple sclerosis (MS) compared with placebo, but researchers reported no significant difference between the two in neurophysiologic measures.
Results from the RADIANCE study show that treatment with the selective S1P1 receptor modulator RPC1063 is associated with significant reductions in GD-enhancing lesions on MRI, as well as new or enlarging T2 lesions, compared with placebo.
Multiple Sclerosis Latest News
Multiple Sclerosis Clinical Trials
Multiple Sclerosis Resources